Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL POLAND SYNDROME MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. INDUSTRY INSIGHTS
2.1 PATENT ANALYSIS
2.1.1 PATENT LANDSCAPE
2.1.2 USPTO NUMBER
2.1.3 PATENT EXPIRY
2.1.4 EPIO NUMBER
2.1.5 PATENT STRENGTH AND QUALITY
2.1.6 PATENT CLAIMS
2.1.7 PATENT CITATIONS
2.1.8 PATENT LITIGATION AND LICENSING
2.1.9 FILE OF PATENT
2.1.10 PATENT RECEIVED CONTRIES
2.1.11 TECHNOLOGY BACKGROUND
2.2 DRUG TREATMENT RATE BY MATURED MARKETS
2.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
2.4 PATIENT FLOW DIAGRAM
2.5 KEY PRICING STRATEGIES
2.6 KEY PATIENT ENROLLMENT STRATEGIES
2.7 INTERVIEWS WITH SPECIALIST
2.8 OTHER KOL SNAPSHOTS
3. EPIDEMIOLOGY
3.1 INCIDENCE OF ALL BY GENDER
3.2 TREATMENT RATE
3.3 MORTALITY RATE
3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
3.5 PATIENT TREATMENT SUCCESS RATES
4. MERGERS AND ACQUISITION
4.1 LICENSING
4.2 COMMERCIALIZATION AGREEMENTS
5. REGULATORY FRAMEWORK
5.1 REGULATORY APPROVAL PROCESS
5.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.3 REGULATORY APPROVAL PATHWAYS
5.4 LICENSING AND REGISTRATION
5.5 POST-MARKETING SURVEILLANCE
5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6. PIPELINE ANALYSIS
6.1 CLINICAL TRIALS AND PHASE ANALYSIS
6.2 DRUG THERAPY PIPELINE
6.3 PHASE III CANDIDATES
6.4 PHASE II CANDIDATES
6.5 PHASE I CANDIDATES
6.6 OTHERS (PRE-CLINICAL AND RESEARCH)
7. MARKETED DRUG ANALYSIS
7.1 DRUG
7.1.1 BRAND NAME
7.1.2 GENERICS NAME
7.2 THERAPEUTIC INDICTION
7.3 PHARMACOLOGICAL CLASS OF THE DRUG
7.4 DRUG PRIMARY INDICATION
7.5 MARKET STATUS
7.6 MEDICATION TYPE
7.7 DRUG DOSAGES FORM
7.8 DOSAGES AVAILABILITY
7.9 DRUG ROUTE OF ADMINISTRATION
7.10 DOSING FREQUENCY
7.11 DRUG INSIGHT
7.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
7.12.1 FORECAST MARKET OUTLOOK
7.12.2 CROSS COMPETITION
7.12.3 THERAPEUTIC PORTFOLIO
7.12.4 CURRENT DEVELOPMENT SCENARIO
8. MARKET ACCESS
8.1 10-YEAR MARKET FORECAST
8.2 CLINICAL TRIAL RECENT UPDATES
8.3 ANNUAL NEW FDA APPROVED DRUGS
8.4 DRUGS MANUFACTURER AND DEALS
8.5 MAJOR DRUG UPTAKE
8.6 CURRENT TREATMENT PRACTICES
8.7 IMPACT OF UPCOMING THERAPY
9. R & D ANALYSIS
9.1 COMPARATIVE ANALYSIS
9.2 DRUG DEVELOPMENTAL LANDSCAPE
9.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
9.4 THERAPEUTIC ASSESSMENT
9.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
10. MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINTS
10.3 OPPORTUNITIES
10.4 CHALLENGES
11. GLOBAL POLAND SYNDROME MARKET, BY TYPE
11.1 OVERVIEW
11.2 UNILATERAL POLAND SYNDROME
11.3 BILATERAL POLAND SYNDROME
12. GLOBAL POLAND SYNDROME MARKET, BY TREATMENT
(NOTE: MARKET VALUE,(USD MILLION), VOLUME(UNIT) AND ASP(USD) WILL BE PROVIDED FOR EACH OF THE SEGMENT)
12.1 OVERVIEW
12.2 SURGERY
12.2.1 THORACIC SURGERY
12.2.2 HAND SURGERY
12.2.3 PLASTIC SURGERY
12.3 EMERGING TREATMENT
12.3.1 RIB GRAFTS
12.3.2 BY MATERIAL
12.3.3 STEEL
12.3.4 ALUMINIUM
12.3.5 OTHERS (IF ANY)
12.3.6 TISSUE EXPANDER
12.3.7 PROSTHETIC IMPLANT
12.3.8 CUSTOM-MADE SILICONE IMPLANT
12.3.9 AUTOLOGOUS FAT INJECTION
12.4 THERAPEUTIC TATTOOING
12.5 PHYSICAL THERAPY
12.6 INJECTIONS
12.7 OTHERS (IF ANY)
13. GLOBAL POLAND SYNDROME MARKET, BY DIAGNOSTIC
13.1 OVERVIEW
13.2 BLOOD TESTS
13.3 ELECTROCARDIOGRAM (ECG)
13.4 CT SCANS
13.5 MRI SCANS
13.6 X-RAY
13.7 PULMONARY FUNCTION TESTS
13.8 GENETIC TESTING
14. GLOBAL POLAND SYNDROME MARKET, BY AGE GROUP
14.1 OVERVIEW
14.2 PEDIATRIC
14.3 ADULT
15. GLOBAL POLAND SYNDROME MARKET, BY GENDER
15.1 OVERVIEW
15.2 MALE
15.3 FEMALE
16. GLOBAL POLAND SYNDROME MARKET, BY SEVERITY
16.1 OVERVIEW
16.2 MILD FORM
16.3 MODERATE FORM
16.4 SEVERE FORM
17. GLOBAL POLAND SYNDROME MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.2.1 BY TIER
17.2.2 TIER 1
17.2.3 TIER 2
17.2.4 TIER 3
17.2.5 BY TYPE
17.2.6 PUBLIC
17.2.7 PRIVATE
17.3 SPECIALITY CLINICS
17.4 DIAGNOSTIC LABORATORIES
17.5 PATHOLOGY LABS
17.6 RESEARCH AND DEVELOPMENT CENTERS
17.7 OTHERS
18. GLOBAL POLAND SYNDROME MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 DIRECT TENDERS
18.3 RETAIL SALES
18.3.1 HOSPITAL PHARMACY
18.3.2 RETAIL PHARMACY
18.3.3 ONLINE PHARMACIES
18.4 OTHERS
19. GLOBAL POLAND SYNDROME MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 MERGERS & ACQUISITIONS
19.6 NEW PRODUCT DEVELOPMENT & APPROVALS
19.7 EXPANSIONS
19.8 REGULATORY CHANGES
19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19.10 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
20. GLOBAL POLAND SYNDROME MARKET, SWOT AND DBMR ANALYSIS
21. GLOBAL POLAND SYNDROME MARKET, BY COUNTRY
21.1 NORTH AMERICA
21.1.1 U.S.
21.1.2 CANADA
21.1.3 MEXICO
21.2 EUROPE
21.2.1 GERMANY
21.2.2 U.K.
21.2.3 FRANCE
21.2.4 ITALY
21.2.5 SPAIN
21.2.6 NETHERLANDS
21.2.7 SWITZERLAND
21.2.8 RUSSIA
21.2.9 BELGIUM
21.2.10 TURKEY
21.2.11 REST OF EUROPE
21.3 ASIA-PACIFIC
21.3.1 CHINA
21.3.2 JAPAN
21.3.3 INDIA
21.3.4 SOUTH KOREA
21.3.5 SINGAPORE
21.3.6 THAILAND
21.3.7 MALAYSIA
21.3.8 AUSTRALIA
21.3.9 VIETNAM
21.3.10 REST OF ASIA-PACIFIC
21.4 SOUTH AMERICA
21.4.1 BRAZIL
21.4.2 ARGENTINA
21.4.3 REST OF SOUTH AMERICA
21.5 MIDDLE EAST AND AFRICA
21.5.1 SOUTH AFRICA
21.5.2 SAUDI ARABIA
21.5.3 UAE
21.5.4 ISRAEL
21.5.5 EGYPT
21.5.6 REST OF MIDDLE EAST AND AFRICA
22. GLOBAL POLAND SYNDROME MARKET, COMPANY PROFILE
22.1 SIEMENS HEALTHINEERS AG
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 GEOGRAPHIC PRESENCE
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 KONINKLIJKE PHILIPS N.V.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 GEOGRAPHIC PRESENCE
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 GE HEALTHCARE
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 GEOGRAPHIC PRESENCE
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 SHIMADZU CORPORATION
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 GEOGRAPHIC PRESENCE
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 CQ MEDICAL
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 GEOGRAPHIC PRESENCE
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENTS
22.6 JOHNSON & JOHNSON SERVICES, INC
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 GEOGRAPHIC PRESENCE
22.6.4 PRODUCT PORTFOLIO
22.6.5 RECENT DEVELOPMENTS
22.7 CHROMOGENEX TECHNOLOGIES LIMITED
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 GEOGRAPHIC PRESENCE
22.7.4 PRODUCT PORTFOLIO
22.7.5 RECENT DEVELOPMENTS
22.8 ALMA LASERS
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 GEOGRAPHIC PRESENCE
22.8.4 PRODUCT PORTFOLIO
22.8.5 RECENT DEVELOPMENTS
22.9 BOLTON SURGICAL LIMITED
22.9.1 COMPANY SNAPSHOT
22.9.2 REVENUE ANALYSIS
22.9.3 GEOGRAPHIC PRESENCE
22.9.4 PRODUCT PORTFOLIO
22.9.5 RECENT DEVELOPMENTS
22.10 STRYKER
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 GEOGRAPHIC PRESENCE
22.10.4 PRODUCT PORTFOLIO
22.10.5 RECENT DEVELOPMENTS
22.11 XRHEALTH
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 GEOGRAPHIC PRESENCE
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPMENTS
22.12 ABBVIE
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 GEOGRAPHIC PRESENCE
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPMENTS
22.13 CYTORI THERAPEUTICS, INC.
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 GEOGRAPHIC PRESENCE
22.13.4 PRODUCT PORTFOLIO
22.13.5 RECENT DEVELOPMENTS
22.14 ASPIRE MEDICAL INNOVATION
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 GEOGRAPHIC PRESENCE
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPMENTS
22.15 MICROAIRE
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 GEOGRAPHIC PRESENCE
22.15.4 PRODUCT PORTFOLIO
22.15.5 RECENT DEVELOPMENTS
22.16 ATI PHYSICAL THERAPY
22.16.1 COMPANY SNAPSHOT
22.16.2 REVENUE ANALYSIS
22.16.3 GEOGRAPHIC PRESENCE
22.16.4 PRODUCT PORTFOLIO
22.16.5 RECENT DEVELOPMENTS
22.17 KLS MARTIN GROUP
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 GEOGRAPHIC PRESENCE
22.17.4 PRODUCT PORTFOLIO
22.17.5 RECENT DEVELOPMENTS
22.18 ANATOMICS PTY LTD
22.18.1 COMPANY SNAPSHOT
22.18.2 REVENUE ANALYSIS
22.18.3 GEOGRAPHIC PRESENCE
22.18.4 PRODUCT PORTFOLIO
22.18.5 RECENT DEVELOPMENTS
22.19 NEXTSTEP ROBOTICS
22.19.1 COMPANY SNAPSHOT
22.19.2 REVENUE ANALYSIS
22.19.3 GEOGRAPHIC PRESENCE
22.19.4 PRODUCT PORTFOLIO
22.19.5 RECENT DEVELOPMENTS
22.20 SILIMED
22.20.1 COMPANY SNAPSHOT
22.20.2 REVENUE ANALYSIS
22.20.3 GEOGRAPHIC PRESENCE
22.20.4 PRODUCT PORTFOLIO
22.20.5 RECENT DEVELOPMENTS
22.21 MTF BIOLOGICS
22.21.1 COMPANY SNAPSHOT
22.21.2 REVENUE ANALYSIS
22.21.3 GEOGRAPHIC PRESENCE
22.21.4 PRODUCT PORTFOLIO
22.21.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23. RELATED REPORTS
24. CONCLUSION
25. QUESTIONNAIRE
26. ABOUT DATA BRIDGE MARKET RESEARCH
